The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now? by Smolen, Josef S et al.
Page 1 of 12
(page number not for citation purposes)
Available online http://arthritis-research.com/content/10/3/208
Abstract
Rheumatoid arthritis is a heterogeneous disease with respect to
clinical manifestations, serologic abnormalities, joint damage and
functional impairment. Predicting outcome in a reliable way to allow
for strategic therapeutic decision-making as well as for prediction
of the response to the various therapeutic modalities available
today, especially biological agents, would provide means for
optimization of care. In the present article, the current information
on biological and clinical markers related to disease activity and
joint damage as well as for predictive purposes is reviewed. It will
be shown that the relationship of many biomarkers with disease
characteristics is confounded by factors unrelated to the disease,
and that only few biomarkers exist with some predictive value.
Moreover, clinical markers appear of equal value as biomarkers for
this purpose, although they likewise have limited capacity in these
regards. The analysis suggests the search for better markers to
predict outcomes and therapeutic responsiveness in rheumatoid
arthritis needs to be intensified.
Introduction: setting the stage
Rheumatoid arthritis (RA) is characterized by many different
phenotypes. Joint involvement, although characteristically
symmetrical, can range from a monoarticular pattern to a
highly polyarticular pattern, and joint damage can span from
mild cartilage degradation to progressive erosive disease of
juxtarticular bone [1,2]. The course of RA may be cyclic or
relentlessly active [3], and extraarticular manifestations such
as rheumatoid nodules or vasculitis may be present. Patients
may be seronegative or may have many different autoanti-
bodies [4]. Variable combinations of all these characteristics
create a broad heterogeneity that is partly manifested by
differences in disease outcomes spanning from remission to
severe disability and premature mortality [5,6]. When thera-
peutic targets are tested in clinical trials and are prescribed in
clinical practice, however, RA is still regarded as a single
disorder.
Biomarkers and clinical markers
Disease activity, joint damage and functional impairment form
the anchor points of the natural history of RA, and are
characterized by a triangular interrelationship (Figure 1). It is
well established that continued disease activity leads to joint
damage, resulting in reduction of physical functioning – and if
damage is progressive, to irreversible disability [7]. For any
clinical and biological marker to be useful, therefore, it should
reflect one or more of the components of the RA triad.
Traditionally, a marker in the present sense should constitute
an indicator or a surrogate with diagnostic or prognostic
utility [8] (Figure 1). A biological marker, then, would be
involved in or would be a consequence of a pathological (or
normal) biological process, a product of the organism that is
measurable and thus bears the attribute of objectivity.
In the context of rheumatic diseases, a typical biomarker
could be a gene or some product of gene expression, an
autoantibody, a cytokine, an acute phase reactant, a tissue
abnormality possibly visualized immunhistochemically in a
synovial biopsy, or a tissue degradation product. The sources
of these biomarkers could be the serum, urine, synovial fluid,
tissue, cells, and so forth.
In contrast, a clinical marker would constitute a physical
variable (sign or symptom), or a clinical judgment or outcome
measurement, that emerges as a sequel of the underlying
disease process. In rheumatology, this variable may be joint
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counts, global or pain assessments and similar clinical
variables, but also composite indices or functional or
radiographic scores (reviewed in [9]). The sources of these
clinical markers are the patients’ manifestations as judged by
an assessor or by the patients themselves, and they conse-
quently carry a certain degree of subjectivity – which is less
easy to standardize than many laboratory measures.
Any biological marker will therefore have to prove its value in
relation to clinical markers, and not necessarily vice versa.
Nevertheless, to be useful as true surrogate markers of
disease, both types of markers have to reflect disease out-
come in a broad sense; namely, a ‘meaningful endpoint of
how a patient feels, functions and survives’ [10]. At present,
therefore, none of the available biological markers or clinical
markers can be employed as surrogate markers, since as
such they would have to be useful as substitutes for a clinical
outcome. Also, a measure that is useful as a biomarker needs
to be validated objectively by demonstration that the labora-
tory test is accurate, reproducible and measures what it is
supposed to. This is not clear for all molecules measured in
body fluids that will be mentioned. With these caveats in
mind, we will nevertheless use the term biomarker or bio-
logical marker in the course of the present review for the
biological measurements discussed here, for the sake of
simplicity and since this term has been frequently used for
these measurements by many experts in the field [11,12].
The present review will address several questions. Can
biologic or clinical markers eventually help to subset patients
into those who may or may not respond therapeutically to a
given medication? Is there evidence that biomarkers as pre-
sumed reflections of pathogenesis are more helpful for
subsetting disease and therapeutic prognostication than
clinical markers? Are biomarkers more sensitive to change
than clinical markers? Do targeted therapies elicit character-
istic biomarker signatures in the sense of a proof of concept?
Biological markers of joint damage
Joint damage in RA is due to changes of cartilage and bone.
Radiologically, cartilage changes are reflected by joint space
narrowing, while erosions signify bone destruction [13].
Different biomarkers will consequently be representative of
these two components of RA joint destruction.
Cartilage and bone markers
Cartilage damage – regardless of its cause – will lead to
changes in matrix composition. Cartilage matrix is composed
of a mesh of type II collagen (COL2), the most abundant
cartilage protein. Collagen consists of three chains that form
a triple helix, with the exception of the nonhelical N-terminal
and C-terminal ends, the telopeptides. In the extracellular
matrix, the collagen molecules are linked to one another by
cross-linking molecules such as pyridinoline; this cross-
linking involves the telopeptides. While the nonhelical parts
are degradable by many enzymes, the helical portion can only
be degraded by mammalian collagenase at a specific site that
yields fragments of one-quarter and three-quarter lengths,
respectively. During cartilage degradation, therefore, different
collagen fragments – such as crosslinked C-terminal and N-
terminal telopeptides – are released (Table 1). Likewise,
alpha chain fragments of collagenase degradation are set
Figure 1
Triad of rheumatoid arthritis and a selection of markers reflecting its respective elements. The triad of rheumatoid arthritis comprises disease
activity–joint damage–disability; a selection of markers that mainly reflect the respective elements of the triad are shown. Over time, the component
of disability related to joint destruction will increase and thus disability becomes progressively less reversible; in contrast, with adequate therapy,
the component of disability related to disease activity will always be reversible [6,7,98].Page 3 of 12
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free and can be measured, such as COL2 three-quarter-long
collagen via the generated carboxyterminal neoepitope.
Within the COL2 network, other components of the cartilage
matrix are interspersed. These components are degraded in
the course of cartilage damage. Among these are aggrecan,
the breakdown products of which can be detected via core
protein, keratan sulfate or chondroitin sulfate epitopes, and
cartilage oligomeric matrix protein.
Bone destruction is an important hallmark of RA, and
therefore the ability to measure its surrogates is important.
The major structural protein of bone is type I collagen, which
like COL2 forms triple helical, cross-linked structures and is
degraded in a similar manner as COL2. Type I collagen C-
terminal telopeptide (CTX-I) and type I collagen N-terminal
telopeptide (NTX-I), but also free pyridinoline crosslinks,
therefore reflect type I collagen degradation. Just like carti-
lage, bone contains noncollagenous proteins, such as bone
sialoprotein, which are released during bone damage (Table 1).
Association with joint damage
Landewe and colleagues have shown a significant correlation
between early changes in type II collagen C-terminal
telopeptide (CTX-II) and prediction of long-term radiographic
progression as a result of therapy; in contrast, changes of
CTX-I were not related to joint damage [14,15]. The changes
in CTX-II levels, however, were broadly overlapping with
baseline values, and were therefore predictive primarily on a
group level. Subanalysis of radiographic changes by joint
space narrowing and erosion scores did not reveal major
differences between these two components of the
radiographic score in relation to these biomarkers [14]. This
analysis indicates that CTX-II levels may at least partly reflect
the inflammatory response (which leads to collagen
degradation via activation of matrix metalloproteinases),
although there was no statistical evidence for such relation-
ship. In contrast, MMP3 levels appear significantly associated
with progression of joint damage [16,17].
Assessment of COL2 three-quarter-long collagen showed
decreasing levels during treatment with methotrexate, and
particularly with anti-TNF + methotrexate [16]. Moreover,
baseline COL2 three-quarter-long collagen concentrations
were significantly associated with cytokine levels [16].
Evaluation of cartilage oligomeric matrix protein levels
revealed that these are much higher in patients whose joint
damage progresses when compared with those whose radio-
graphic changes do not progress [18]. These observations
as well as the CTX-II data were recently confirmed [17],
although there was again broad overlap in biomarker levels of
patients with and without progression of joint damage. Yet
none of these markers performed better than C-reactive
protein (CRP), swollen joint counts or composite disease
activity indices [17].
Another set of markers potentially useful to assess bone
damage relates to osteoclast differentiation and function.
Osteoclasts that derive from bone marrow progenitor cells via
the monocyte lineage are the cell population responsible for
erosive changes [19,20] and are pivotally dependent on the
triggering of receptor activator of NFκB. The receptor
activator of NFκB ligand (RANKL), a member of the TNF
family, is expressed on various cell populations and also
exists as a soluble molecule [21]. The ligand’s action can be
inhibited by osteoprotegerin, a decoy receptor. Both osteo-
protegerin and RANKL can be measured in serum, and the
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Table 1
Markers of degradation of cartilage and bone
Tissue Molecule Marker of degradation Designation
Cartilage Type II collagen Pyridinoline PYD
Type II collagen C-terminal and N-terminal telopeptides CTX-II, NTX-II
Type II collagen alpha chain fragments  Col2-3/4 long, Col2-3/4C short
Aggrecan Core protein fragments
Keratan sulfate fragments
Noncollagen and  Cartilage oligomeric matrix protein COMP
nonaggrecan proteins
Bone Type I collagen  Pyridinoline, deoxypyridinolin PYD, DPD
Type I collagen C-terminal and N-terminal telopeptides CTX-I, NTX-I
Noncollagenous Bone  sialoprotein BSP
proteins
Tartrate-resistant acid phosphatase TRAPosteoprotegerin/RANKL ratio may be an indicator of osteo-
clast differentiation and activation. In fact, a low osteo-
protegerin/RANKL ratio, reflecting high RANKL activity, appears
to be associated with increased progression of radiographic
joint damage [22]. Osteoclasts mediate their special function
in degrading calcified bone by several mechanisms, including
secretion of cathepsin K. Consequently, cathepsin K levels
correlate with joint destruction [23] and may be reflective of
effective therapy [24].
Despite some interesting, although mostly inconclusive, data in
the literature, there are a number of confounding factors related
to the usefulness of many of these bone and cartilage
breakdown products in helping to subgroup and treat RA. First,
comorbidity, such as osteoarthritis and especially generalized
osteoporosis [25], may lead to collagen degradation and thus
obscure the subtle changes observed. Another factor is that
circadian variations in bone and cartilage marker levels have
been described (that is, the timing of the measurement is
critical) [26,27]. Third, physical activity may change biomarker
concentrations significantly [28]. A fourth factor is that renal or
hepatic disease may influence circulating and/or urine levels of
biomarkers [29]; especially, urine biomarkers should always be
related to creatinine levels [11]. Finally, the tissue content
and/or levels of certain proteins that constitute useful
biomarkers may be genetically determined, and this heritability
may have to be accounted for [30]. These factors contribute to
the complexity of monitoring cartilage and bone turnover in RA
as they relate to predicting joint damage [31]. In an individual
patient, however, short-term changes in the course of
therapeutic interventions aimed at interfering with the RA
process ought to reflect the modification of that process.
Another set of markers that is not derived from cartilage or
bone may be predictive of joint damage: autoantibodies. It
has long been recognized that radiographic progression of
joint destruction is much higher in patients positive for
rheumatoid factor when compared with seronegative patients
[32-35]. This is particularly true in patients with high-titer
rheumatoid factor; that is, rheumatoid factor ≥ 50 IU/ml [36].
Autoantibodies to citrullinated proteins have been shown
more recently to be predictive for the occurrence of erosions
[36,37]; the autoantibodies are broadly overlapping with
high-titer rheumatoid factor, and the latter appears to change
with effective therapy more than the autoantibodies to
citrullinated proteins [35,36,38,39]. These markers of the
autoimmune response characteristic of RA surpass the value
of most cartilage and bone breakdown products in predicting
joint damage. At present, the combination of autoantibody
and acute phase protein assessment may constitute the most
reliable way to predict severe erosive RA [33,40].
Biological markers of disease activity
Cells and cytokines
The clinical manifestations of RA are the consequences of
synovial inflammation and the subsequent degradation and
destruction of cartilage and bone. These pathways comprise
various cell populations characteristically involved in RA
synovitis as well as cytokines and the products of their action.
When looking at arthroscopic biopsies, the composition of
the cellular infiltrate is heterogeneous [41,42], and the most
consistent reflection of active disease is the presence of
high numbers of macrophages in the synovium [43,44].
Potent anti-inflammatory agents such as glucocorticoids
lead to a reduction in synovial macrophage cellularity (but
little other cellular changes) [45]. Interestingly, blocking
other mediators such as the chemokine macrophage chemo-
attractant protein MCP-1 was not associated with changes
of synovial tissue composition or with clinical benefit
[39,46]. In addition, the degree of B-cell depletion in
synovial tissue in the course of rituximab therapy was not
significantly associated with the clinical response and
B cells may be present in the synovium even if depelted in
peripheral blood [39,47]. This finding also indicates that the
periphery often does not reflect the events occurring in the
joint, but these by themselves are also not sufficiently
predictive.
With the exception of macrophage infiltrates, therefore, the
composition and extent of the cellular infiltrate may not be
related to clinical manifestations, in line with observations of
histologic synovitis in the absence of clinical joint involvement
[48]. Likewise, the immunohistochemistry of cytokines may
not sufficiently reflect the disease activity of RA. The use of
gene expression profiling currently does not appear to
provide much additional information in this respect [49,50],
although the technique may be useful to detect unforeseen
changes. Serum levels of proinflammatory cytokines –
including the most abundant one, IL-6 – are not highly
correlated with measures of disease activity and progression
[51,52]; moreover, baseline IL-6 concentrations may vary
almost 100-fold between different individuals, and can
increase with exercise [53].
Qualitative and/or quantitative differences exist among
individual patients both on the cellular level and the cytokine
level [54,55], and pathohistologic analyses have failed to
reveal changes that are pathognomonic for RA. Synovial cyto-
kine expression in RA, even at a group level, does not signifi-
cantly differ qualitatively from other arthritic disorders [56-58].
Nevertheless, there appear to be differences in the quantity of
cytokine expression when looking at other inflammatory joint
diseases, such as psoriatic arthritis, ankylosing spondylitis or
inflammatory osteoarthritis. Patients with these conditions
have lower synovial TNF and IL-6 levels than RA patients
[58,59]. These differences may have some important bearing
given that RA is a rapidly and highly destructive joint disease,
while the other disorders are usually slowly or not as destructive.
All these facets reveal the complexity we face when trying to
search for good biomarkers. The complexity is further
Arthritis Research & Therapy    Vol 10 No 3 Smolen et al.
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markers early in the course of RA may be quite different from
those seen in late disease [60], regardless of the level of
activity or inflammation in either early or late disease.
To better appreciate the complexity, we present four
hypothetical patients in whom different cytokines or different
cell populations may appear to predominate, even though in
all patients many cells or soluble molecules are at least partly
activated (Figure 2).
The resolution of this mosaic will be difficult: changes of
biomarker levels in the course of therapy may give helpful
insights, but this knowledge is insufficient to provide
prediction rules for the employment of specific therapies.
Acute phase reactants
In contrast to the markers mentioned above, the serum levels
of CRP, a molecule induced by proinflammatory cytokines,
especially IL-6 [61], not only reflect the extent of disease
activity [62,63] but are also cumulatively associated with joint
destruction [17,63,64]. Moreover, CRP levels before the start
of disease-modifying therapy can predict the degree of
subsequent radiographic joint damage, and greater reduction
from baseline in CRP levels was associated with less
progression of joint damage and higher trough serum
concentrations of anti-TNF antibody [65,66]. While other
acute phase reactants, such as serum amyloid A protein, also
reflect disease activity, CRP determination is widely available
and of low cost [67], making it the preferred biomarker of
disease activity (and even joint destruction) not yet surpassed
by other markers.
The erythrocyte sedimentation rate could be regarded as an
alternative to measuring CRP. However, it may be influenced
by various other factors not primarily related to inflammation
[68]. Successful therapeutic interventions with
glucocorticoids and disease-modifying antirheumatic drugs
(DMARDs) including biological agents are usually associated
with a fall in CRP levels, and are often also paralleled by
reductions in IL-6 serum concentrations [24,69,70].
It is somewhat disappointing that levels of other marker mole-
cules, such as various cytokines, cytokine receptors or matrix
metalloproteinases, have not been shown to exhibit better
correlations with actual disease manifestations or outcomes
of RA than acute phase reactants. No biological marker
assessed hitherto has therefore been shown to be related
better to disease activity and joint damage than CRP.
Clinical markers
Biological markers have to reflect diagnosis and/or prog-
nosis; that is, clinical outcomes [10,71]. The extent of this
association will determine the reliability and value of the
marker. As revealed above, with the exception of the acute
phase response and autoantibodies, no biological marker is
currently sufficiently reliable to acknowledge its usefulness as
a marker of disease activity or joint damage for use in clinical
practice. Markers of disease activity, however – especially
composite indices using some of the core set variables, such
as the Disease Activity Score employing 28 joint counts, the
Simplified Disease Activity Index and the Clinical Disease
Activity Index (reviewed in [9]) – have been shown useful for
following disease activity and for serving as endpoints in
clinical trials and observational studies [72,73]. Moreover,
disease activity over time as assessed using these indices
correlates significantly with progression of joint damage [63].
These data suggest that clinical markers, even in the absence
of any laboratory variable such as is the case with the Clinical
Disease Activity Index [63], may serve the purpose of
predicting joint damage at least as well as any biological
marker. In fact, time-averaged disease activity using these
composite indices correlated with radiographic progression
better than time-averaged CRP [63].
Prediction of clinical improvement and retardation of
joint damage
No biomarker currently allows one to predict the extent of
clinical improvement in response to therapy, although the
degree of radiographic progression on traditional disease-
modifying agents can be foretold by baseline and cumulative
levels of CRP, swollen joint counts or overall disease activity
using respective composite scores [65].
In this context it needs to be borne in mind that TNF and IL-6
are cytokines that promote osteoclast differentiation and
activation [20,21,74-77]. Importantly, under stable low
concentrations of RANKL, increasing amounts of proinflam-
matory cytokines, such as TNF, will lead to increasing osteo-
clast differentiation [78]. It is therefore conceivable that this
relation of TNF levels and osteoclast activation also exists in
vivo. In support of this notion, treatment of RA patients with a
TNF inhibitor plus methotrexate leads to a dissociation of the
close relationship between joint damage and the
inflammatory response (exemplified by disease activity
measures) [79], and these data were meanwhile confirmed
with another TNF-blocker [80]. These findings have led to the
threshold hypothesis shown in Figure 3. According to this
hypothesis, TNF will lead to joint damage especially once its
levels exceed a particular threshold that lies above the
threshold needed for the activation of the inflammatory
response. Blocking of TNF may inhibit its bioactivity fully
(Figure 3b), may reduce bioactivity to levels below the
putative threshold of destruction with residual signs and
symptoms but no destruction (Figure 3c), or may reduce
bioactivity to levels above that threshold but still significantly
retard joint damage compared with other treatment
modalities, without preventing progression in full (Figure 3d).
This hypothesis is in line with results from clinical trials where
the use of TNF inhibitors significantly retarded or halted joint
destruction despite residual active disease [81-83].
Available online http://arthritis-research.com/content/10/3/208
Page 5 of 12
(page number not for citation purposes)Whilst the focus of attention with respect to joint damage has
primarily been the osteoclast, it should be borne in mind that
bone repair mechanisms may be deficient in TNF-mediated
arthritis and can be induced by osteoblast activation [84].
Biomarkers of osteoblast function, including proteins involved
in the Wnt signaling pathways [85], may therefore constitute
further interesting markers for the future.
Importantly, however, achieving low disease activity or
remission with traditional DMARDs will lead to highly effective
reduction of progression of joint damage [86]. Another
important aspect in our attempts to predict outcomes is
therefore the estimation of the clinical response to treatment.
Recent analyses in a large cohort of clinical trial patients have
revealed that baseline disease activity is already somewhat
related to disease activity at 1 year of therapy, especially with
methotrexate treatment [87]. Irrespective of the type of therapy
or disease duration, however, 3 months after initiation of
treatment the disease activity – as assessed by the Simplified
Disease Activity Index, the Clinical Disease Activity Index or
the Disease Activity Score employing 28 joint counts – was
highly correlated with disease activity at the end of the
observation period [87] (Figure 4). These data were further
validated by studying an observational cohort of RA patients
[88]. The probability to attain remission or low disease activity
was more than 75% for patients achieving low disease
activity by the Simplified Disease Activity Index already after
3 months of treatment, while it amounted to only 25% for
patients having high disease activity at that point in time [87].
Needless to say, achieving lower disease activity after
3 months of therapy will also result in better outcomes in the
other components of the triad – physical function and joint
damage. Moreover, starting effective treatment early, and
especially before initial damage has occurred, constitutes the
optimal strategy (Figure 5). This optimization, however, requires
early referral and early diagnosis [89,90]. Moreover, there is
sufficient evidence to allow stating that DMARDs will interfere
with the disease process at any point in time and will prevent
progression of disease regardless of patient age or disease
duration – it is the past damage that has to be carried on.
Arthritis Research & Therapy    Vol 10 No 3 Smolen et al.
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Figure 2
Depiction of potential cytokine and cellular patterns in four hypothetical patients with rheumatoid arthritis. Upper panel: hypothetical biological
activities of various cytokines. Lower panel: hypothetical biological activities of various cell types. y axis, arbitrary units of activity. For example, in
patient #1 TNF does not appear bioactive, while in patient #3 B cells appear uninvolved. Especially in patient #4, however, all cytokines – and in
patient #1 all cell types – appear actively engaged in the disease process. In patient #2 IL-6 may not be detectable. It is unclear to what extent
which of those cells and/or cytokines is contributing and if one or several targeted therapies would be efficacious. Although such relationships
have not yet been elucidated, differences in synovial cellular compositions and cytokine contents have been noted in various studies [55,59,99].
DC, dendritic cells; Fib, fibroblasts.Complexity of rheumatoid arthritis
The ability to ulitilize biologic markers and or clinical markers
to predict disease outcomes as well as therapeutic response
early in the course of the disease, so as to achieve remission,
is our ultimate goal in RA. We have indicated that predicting
disease outcome and therapeutic response may be difficult
due to the heterogeneity of the disease regarding both its
clinical manifestations as well as putative pathogenic charac-
teristics. Contributing to this has been the observed variability
of biomarker levels. Data presently reveal that different
therapeutic agents, including targeted therapies directed
against different molecules, lead to similar therapeutic
responses. To which degrees these responsive populations
overlap, however, is currently unclear: do most of the patients
achieving an American College of Rheumatology 70%
response (or remission) to one drug have different
characteristics than patients responding to a similar extent to
another agent, or are they overlapping? Answers to these
questions are mandatory for institution of proper treatment to
gain control of disease and to induce remission.
Conclusion
Many biological markers reflect the ongoing disease process
of RA. The markers’ correlation to the typical manifestations
of RA, the signs and symptoms of active disease, the
destruction of joints or the impairment of physical function,
however, has been poor for most of them. This may be due to
a variety of reasons. First, what we measure in various body
fluids may not reflect sufficiently well what is ongoing in the
microenvironment of the joint, and the leakage of various
molecules into the body fluids may differ among, and within,
patients. Second, where biomarkers have important patho-
physiological functions, the concentrations measured may not
reflect their functional fraction. Third, the pathogenesis of RA
Available online http://arthritis-research.com/content/10/3/208
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Figure 3
Threshold hypothesis of osteoclast activation. (a) Osteoclast activation is assumed to occur only after passing a putative threshold. (b) Anti-TNF
therapy may ideally lead to total inhibition of bioactive TNF. (c) In other patients, anti-TNF therapy may reduce TNF activity below the threshold of
osteoclast activation; these patients may continue having signs and symptoms of rheumatoid arthritis. (d) In yet another group of patients, the TNF
activity may be reduced, but not to a level that goes below the threshold of osteoclast activation; in these patients, there will be more inflammation
than in (c) and some residual destruction – in relation to other therapies, such as methotrexate, the destruction will be significantly less at a similar
level of inflammatory signs and symptoms of rheumatoid arthritis [79]. CDAI, Clinical Disease Activity Index; CRP, C-reactive protein.may be highly heterogeneous, with different markers being
preponderate in different patients. Fourth, pathogenetic
mechanisms may even vary within a patient in the course of
the disease. Finally, diurnal and genetic variations may
change biomarker levels and confound our ability to interpret
them – with relatively low levels in one patient being highly
pathogenic, while a high level in another patient may mean
little for that particular patient’s disease.
Importantly, we have focused here on markers that are
frequently used to evaluate disease activity, cartilage and
bone damage. There is more going on in relation to the
immunopathogenic events, however, than mere production of
cytokines and the consequences of their activity. For example,
certain T-cell subpopulations have shown changes in active
RA [91,92]. The application of such markers in practice, how-
ever, is limited by the lack of widespread availability of the
Arthritis Research & Therapy    Vol 10 No 3 Smolen et al.
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Figure 4
Time course of disease activity in patients attaining particular disease activity states after 1 year of therapy. Patients who achieved low disease
activity or remission at 1 year attained a low disease activity state within 3 to 6 months from the onset of treatment. SDAI, Simplified Disease
Activity Index. Reproduced with permission from [87].
Figure 5
Effect of disease-modifying antirheumatic drug therapy. Disease-modifying antirheumatic drugs (DMARDs) will interfere with the disease process at
any time point, and will lead to a deflection of the slope of progression from its natural course. The ideal situation would be to diagnose and treat
rheumatoid arthritis early; at best, before damage has occurred.respective detection techniques. Also, some imaging tech-
niques, such as magnetic resonance imaging and ultrasound,
may allow new insights and may contribute interesting
information on disease activity or even outcome [93-95].
More information is presently needed, and the search for the
best set of biomarkers for assessment and prediction of disease
activity, damage and response to therapy as well as efforts to
better standardize biomarker assessment must, and will, go on.
Appropriate cohorts of patients and appropriate validation
procedures will be needed to this end. For the time being it
appears too early to recommend the use of these markers in
routine practice or as major outcomes in clinical trials. System
biologic approaches may provide better insights in the not too
distant future [96], but their applicability in routine settings will
constitute yet another challenge. Likewise, proteomic
approaches employing various methodological means may
prove helpful, but at present merely confirm the complexity of
the biological interplay we are dealing with in RA [97].
There are two exceptions, however, which make the above
summary much less disappointing: acute phase reactants,
especially CRP, are highly reliable markers of disease activity
and, in the long term, radiographic outcomes; and auto-
antibodies, especially rheumatoid factor and autoantibodies
to citrullinated proteins, have diagnostic and prognostic
value. That these old markers surpass the value of new ones
and that some of the old techniques employed for marker
determination may be more reliable than new ones sounds
inadequate, but nevertheless it is satisfying that such useful-
ness and validity does exist for at least few molecules.
Equally important, research activities of the past decade have
allowed one to obtain clinical assessment tools – the
composite disease activity indices, which are not only reliable
for assessing the wellbeing of patients with RA during follow
up, but are also highly associated with functional and radio-
logical disease outcome. A combination of such tools with a
novel approach to biomarker evaluation may therefore allow
for optimized understanding and prediction of the fate of the
individual RA patient. There is recognition that clinical
assessment (measuring and noting the change in index and
the disease activity state attained) early in the course of
therapy (3 to 6 months after initiation of therapy) allows one
to judge longer-term treatment effects and to make rapid
changes of therapeutic modalities in the individual patients in
whom low disease activity is not achieved. Such a strategy
will consequently be associated with lesser costs by avoiding
prolonged use of ineffective therapies and will also lead to a
better outcome of RA.
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